Abstract
Despite high complete remission (CR) rates, relapse remains a significant problem among subsets of patients with B acute lymphoblastic leukemia (ALL), and is associated with poor prognosis. The recent Food and Drug Administration approval of highly effective immunotherapies for B-lineage ALL (B-ALL), blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel, a chimeric antigen receptor (CAR) modified T-cell therapy, targeting CD19, or CD22, have dramatically changed the therapeutic landscape for the treatment of B-ALL, resulting in high rates of deep and durable remissions. Therefore, there is now debate regarding the role of allogeneic hematopoietic cell transplantation (HCT) in this new landscape. Herein, we review these novel agents, and discuss the sequence of therapy, including allogeneic HCT in B-ALL.
References
Aug 2, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Denise M OlianskyTheresa Hahn
Feb 24, 2012·The Lancet Oncology·Hagop KantarjianSusan O'Brien
Feb 21, 2014·Science Translational Medicine·Marco L DavilaRenier Brentjens
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Oct 17, 2014·Lancet·Daniel W LeeCrystal L Mackall
Dec 20, 2014·The Lancet Oncology·Max S ToppHagop M Kantarjian
Jan 27, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer N BrudnoJames N Kochenderfer
Apr 26, 2016·The Journal of Clinical Investigation·Cameron J TurtleDavid G Maloney
Jun 14, 2016·The New England Journal of Medicine·Hagop M KantarjianAnjali S Advani
Oct 27, 2016·Experimental Hematology·Xiaoou Zhou, Malcolm K Brenner
Aug 3, 2016·The Journal of Clinical Investigation·Partow KebriaeiLaurence J N Cooper
Sep 8, 2016·Cancer·Elias JabbourHagop M Kantarjian
Dec 7, 2016·Blood·Nitin JainMarina Konopleva
Dec 22, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arend von StackelbergLia Gore
Jan 27, 2017·Science Translational Medicine·Waseem QasimPaul Veys
Mar 2, 2017·The New England Journal of Medicine·Hagop KantarjianMax S Topp
Mar 30, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giovanni MartinelliAnthony Stein
Apr 15, 2017·Blood·Rebecca A GardnerMichael C Jensen
May 12, 2017·Leukemia·J PanC R Tong
Sep 20, 2017·Nature Reviews. Clinical Oncology·Sattva S NeelapuElizabeth J Shpall
Nov 21, 2017·Nature Medicine·Terry J FryCrystal L Mackall
Jan 21, 2018·The Lancet Oncology·Hagop KantarjianElias Jabbour
Jan 24, 2018·Blood·Nicola GökbugetRalf C Bargou
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Feb 1, 2018·The New England Journal of Medicine·Jae H ParkMichel Sadelain
Sep 30, 2018·Leukemia·Deepa BhojwaniSusan R Rheingold
Oct 12, 2018·Cancer·Elias JabbourHagop M Kantarjian
Dec 29, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel W LeeSattva S Neelapu
Feb 8, 2019·Blood·Kevin A HayCameron J Turtle
Mar 29, 2019·Cancer·Hagop M KantarjianAnjali S Advani
Aug 23, 2019·Bone Marrow Transplantation·Elad Jacoby
Aug 23, 2019·Cancer·Elias J JabbourAnthony S Stein
Dec 4, 2019·Leukemia Research·Elias JabbourHagop Kantarjian
Jan 9, 2020·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 15, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nirali N ShahTerry J Fry